Maravai: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $4.5

Wells Fargo maintains 'Overweight' rating on Maravai(MRVI).

The target price is $4.5, compare with $4 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-12-15	Wells Fargo	Maintains	Overweight	Overweight	$4.5	$4

[Recent Earning Results] Maravai posted the Q3 of its 2025 financial results on 11/7/2025, reporting total revenue of USD 135.88 million in the first three quarters, down 32.94% from USD 202.63 million year over year, reporting net income of USD -167.75 million in the first three quarters, narrowing 21.45% from USD -213.56 million year over year.

[Company Profile] Maravai Lifesciences Holdings, Inc. was incorporated in Delaware on August 25, 2020. The company is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases.